{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T12:19:17Z","timestamp":1769861957266,"version":"3.49.0"},"reference-count":37,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Imatinib is an oral tyrosine kinase inhibitor (TKI) and first\u2010line therapy for patients with chronic myeloid leukemia (CML). There is a positive correlation between serum imatinib concentrations and treatment response. However, the specific relationship between the blood concentration of imatinib and its influencing factors remains unclear. This study collected basic information from 102 patients using imatinib as first\u2010line treatment for CML. Further, we analyzed the individual differences in imatinib concentration and explored its influencing factors. Through intra\u2010day and inter\u2010day precision studies, we found that the precision for the imatinib assay methodology was within \u00b113% and that the recovery rate was above 85%. There is notable individual variation in the blood concentration of imatinib; the recommended treatment concentration is 860\u20101500\u00a0ng\/mL, with only 41.40% of patients achieving this concentration. Also, there was a negative correlation between age and imatinib trough concentration (C<jats:sub>trough<\/jats:sub>), as is observed between age and <jats:italic>N<\/jats:italic>\u2010desmethyl imatinib. Moreover, compared with the adolescent group, the serum imatinib C<jats:sub>trough<\/jats:sub> for groups aged 17\u201047 and 48\u201068\u00a0years was significantly reduced. Further analysis shows that imatinib C<jats:sub>trough<\/jats:sub> values reaching therapeutic concentrations (59%) increased dramatically for patients with CML aged 17\u201047\u00a0years. Moreover, groups dosed with 400\u00a0mg\/day resulted in therapeutic imatinib concentrations for 68% of patients with CML, which was the best performance. The established method was validated, with acceptable accuracy, precision, linearity, and stability, as required, and then successfully applied to the therapeutic drug monitoring of imatinib. Age, dose, and metabolites can influence the imatinib concentration and its therapeutic effect in patients with CML.<\/jats:p>","DOI":"10.1002\/jcph.2329","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T05:40:52Z","timestamp":1691732452000},"page":"1438-1447","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic Drug Monitoring of Imatinib and <i>N<\/i>\u2010Desmethyl Imatinib in Chronic Myeloid Leukemia Patients Using LC\u2010MS\/MS in a Cohort Study"],"prefix":"10.1002","volume":"63","author":[{"given":"Xiaoxing","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Blood Transfusion Zhongnan Hospital of Wuhan University  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Tongji Hospital Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Tongji Hospital Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Tongji Hospital Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufeng","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Tongji Hospital Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Tongji Hospital Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,9]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy159"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15369"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-12-0071"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.3912"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-077958"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000324900"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2019.20.11.3331"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2016.1151356"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.139337"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003262101"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126874"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl273"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2015.436"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000167"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1485907"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13327"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12007"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1286"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b15-00103"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31823cdec9"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.11.028"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-1208.97779"},{"issue":"2","key":"e_1_2_10_26_1","first-page":"347","article-title":"Imatinib quantification in human serum for clinical purposes using high\u2010performance liquid chromatography with a diode array detector","volume":"58","author":"Dziadosz M","year":"2011","journal-title":"Acta Chim Slov"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4022"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000357"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000406"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.4010"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S42902"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225225"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2019.07.025"},{"issue":"3","key":"e_1_2_10_34_1","first-page":"147","article-title":"Imatinib quantification in human serum with LC\u2010MS3 as an effective way of protein kinase inhibitor analysis in biological matrices","volume":"32","author":"Dziadosz M","year":"2017","journal-title":"Drug Metab Pers Ther"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000440"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13725"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004770"},{"issue":"9","key":"e_1_2_10_38_1","first-page":"841","article-title":"[Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients]","volume":"22","author":"Yang LX","year":"2019","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T12:41:30Z","timestamp":1699533690000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1002\/jcph.2329"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2329","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"2023-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}